41 related articles for article (PubMed ID: 23743300)
1. Adenosine A₂A receptor agonist-mediated increase in donor-derived regulatory T cells suppresses development of graft-versus-host disease.
Han KL; Thomas SV; Koontz SM; Changpriroa CM; Ha SK; Malech HL; Kang EM
J Immunol; 2013 Jan; 190(1):458-68. PubMed ID: 23225892
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo.
Parmar S; Liu X; Najjar A; Shah N; Yang H; Yvon E; Rezvani K; McNiece I; Zweidler-McKay P; Miller L; Wolpe S; Blazar BR; Shpall EJ
Blood; 2015 Feb; 125(9):1502-6. PubMed ID: 25428215
[TBL] [Abstract][Full Text] [Related]
3. Donor regulatory T cells rapidly adapt to recipient tissues to control murine acute graft-versus-host disease.
Dittmar DJ; Pielmeier F; Strieder N; Fischer A; Herbst M; Stanewsky H; Wenzl N; Röseler E; Eder R; Gebhard C; Schwarzfischer-Pfeilschifter L; Albrecht C; Herr W; Edinger M; Hoffmann P; Rehli M
Nat Commun; 2024 Apr; 15(1):3224. PubMed ID: 38622133
[TBL] [Abstract][Full Text] [Related]
4. Engineering donor lymphocytes with Fas ligand protein effectively prevents acute graft-versus-host disease.
Shrestha P; Turan A; Batra L; Gulen AE; Sun Z; Tan H; Askenasy N; Shirwan H; Yolcu ES
Blood Adv; 2023 May; 7(10):2181-2195. PubMed ID: 36780582
[TBL] [Abstract][Full Text] [Related]
5. Treatment with Mesenchymal Stromal Cells Overexpressing Fas-Ligand Ameliorates Acute Graft-versus-Host Disease in Mice.
Vacaru AM; Mazilu AM; Dumitrescu M; Fenyo IM; Gafencu AV; Vacaru AM
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008964
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-Mediated
Dumitrescu M; Trusca VG; Savu L; Stancu IG; Ratiu AC; Simionescu M; Gafencu AV
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825521
[TBL] [Abstract][Full Text] [Related]
7. Localized Immunomodulation with PD-L1 Results in Sustained Survival and Function of Allogeneic Islets without Chronic Immunosuppression.
Batra L; Shrestha P; Zhao H; Woodward KB; Togay A; Tan M; Grimany-Nuno O; Malik MT; Coronel MM; García AJ; Shirwan H; Yolcu ES
J Immunol; 2020 May; 204(10):2840-2851. PubMed ID: 32253240
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.
Du W; Cao X
Front Immunol; 2018; 9():2979. PubMed ID: 30631325
[TBL] [Abstract][Full Text] [Related]
9. Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.
Zhang L; Yu J; Wei W
Front Immunol; 2018; 9():1087. PubMed ID: 29868032
[TBL] [Abstract][Full Text] [Related]
10. TGF-β1 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice.
Haribhai D; Luo X; Chen J; Jia S; Shi L; Schroeder JA; Weiler H; Aster RH; Hessner MJ; Hu J; Williams CB; Shi Q
Blood Adv; 2016 Dec; 1(2):139-151. PubMed ID: 28164173
[TBL] [Abstract][Full Text] [Related]
11. Novel technologies to engineer graft for tolerance induction.
Woodward KB; Wang F; Zhao H; Yolcu ES; Shirwan H
Curr Opin Organ Transplant; 2016 Feb; 21(1):74-80. PubMed ID: 26626421
[TBL] [Abstract][Full Text] [Related]
12. Impaired T-cell survival promotes mucosal inflammatory disease in SHIP1-deficient mice.
Park MY; Srivastava N; Sudan R; Viernes DR; Chisholm JD; Engelman RW; Kerr WG
Mucosal Immunol; 2014 Nov; 7(6):1429-1439. PubMed ID: 24781051
[TBL] [Abstract][Full Text] [Related]
13. Apoptotic signaling through Fas and TNF receptors ameliorates GVHD in mobilized peripheral blood grafts.
Mizrahi K; Yaniv I; Ash S; Stein J; Askenasy N
Bone Marrow Transplant; 2014 May; 49(5):640-8. PubMed ID: 24566711
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulation with donor regulatory T cells armed with Fas-ligand alleviates graft-versus-host disease.
Yolcu ES; Kaminitz A; Mizrahi K; Ash S; Yaniv I; Stein J; Shirwan H; Askenasy N
Exp Hematol; 2013 Oct; 41(10):903-11. PubMed ID: 23743300
[TBL] [Abstract][Full Text] [Related]
15. Recipient type-specific engineered regulatory T cells prevent graft-vs-host disease after allogeneic bone marrow transplantation in mice.
Chen C; Cao J; Zeng L; Li Y; Wang D; Xu K
Transplant Proc; 2011 Jun; 43(5):2041-8. PubMed ID: 21693322
[TBL] [Abstract][Full Text] [Related]
16. Depletion of naïve lymphocytes with fas ligand ex vivo prevents graft-versus-host disease without impairing T cell support of engraftment or graft-versus-tumor activity.
Askenasy N; Mizrahi K; Ash S; Askenasy EM; Yaniv I; Stein J
Biol Blood Marrow Transplant; 2013 Feb; 19(2):185-95. PubMed ID: 23078782
[TBL] [Abstract][Full Text] [Related]
17. Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts.
Giorgini A; Noble A
J Leukoc Biol; 2007 Nov; 82(5):1053-61. PubMed ID: 17684039
[TBL] [Abstract][Full Text] [Related]
18. Role of naturally arising regulatory T cells in hematopoietic cell transplantation.
Nguyen VH; Zeiser R; Negrin RS
Biol Blood Marrow Transplant; 2006 Oct; 12(10):995-1009. PubMed ID: 17084366
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo expansion of regulatory T cells for clinical applications against graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
Zhang LF; Xia CQ
Chin Med J (Engl); 2013 Dec; 126(23):4575-82. PubMed ID: 24286428
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
